NYSE:PFEPharmaceuticals
A Look at Pfizer's Valuation Following FDA Approval of PADCEV Combination Therapy for Bladder Cancer
Pfizer (NYSE:PFE) and Astellas Pharma have secured FDA approval for PADCEV, combined with Keytruda, as a treatment before and after surgery for muscle-invasive bladder cancer in adults unable to receive cisplatin-based chemotherapy. This regulatory decision is based on encouraging Phase 3 trial data and marks an important step for Pfizer's oncology pipeline and broader portfolio strategy.
See our latest analysis for Pfizer.
The recent FDA approval adds further momentum to Pfizer’s push beyond...